Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT05469113
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT05468164
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT05469126
- Locations
- πΈπ¬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT05469100
- Locations
- πΊπΈ
Orange County Research Center, Tustin, California, United States
πΊπΈStanford Health Care, Valley Care Program, Pleasanton, California, United States
πΊπΈAnaheim Regional Center, Anaheim, California, United States
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1667
- Registration Number
- NCT05463731
- Locations
- πΊπΈ
ClinCloud - Viera, Melbourne, Florida, United States
πΊπΈCentral Texas Neurology Consultants, Round Rock, Texas, United States
πΊπΈThe University of Texas Health Science Center at Houston, Houston, Texas, United States
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 692
- Registration Number
- NCT05463744
- Locations
- πΊπΈ
Palm Research Center Tenaya, Las Vegas, Nevada, United States
πΊπΈBiopharma Informatic, LLC, Houston, Texas, United States
πΊπΈAmir A Hassan, MD, PA, Houston, Texas, United States
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 730
- Registration Number
- NCT05462756
- Locations
- πΊπΈ
Palm Research Center Tenaya, Las Vegas, Nevada, United States
πΊπΈPalm Research Center Sunset, Las Vegas, Nevada, United States
πΊπΈBiopharma Informatic, LLC, Houston, Texas, United States
A Study of LY3537021 in Healthy Participants
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT05444569
- Locations
- πΈπ¬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT05444556
- Locations
- πΊπΈ
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
πΊπΈQps-Mra, Llc, South Miami, Florida, United States
πΊπΈICON Early Phase Services, San Antonio, Texas, United States
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05445232
- Locations
- πΊπΈ
Covance Dallas, Dallas, Texas, United States
πΊπΈCovance Clinical Research Unit, Daytona Beach, Florida, United States